Search Results

Business

GenScript ProBio and Eutilex Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs

GenScript Biotech Corporation’s CDMO business GenScript ProBio (hereinafter referred to as GenScript ProBio) and Eutilex Co., Ltd. (hereinafter referred to as Eutilex) committed to developing anti-cancer immunotherapy technology jointly announced that the parties entered into strategic collaboration

April 7, 2020

·

4 min read

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market.

January 26, 2021

·

2 min read

Business

Eutilex and Huahai Enter Immuno-Oncology Partnership

Under the agreement, Huahai takes a $30M equity stake in Eutilex and receives an exclusive license to develop and commercialize EU-101.

November 6, 2017

·

5 min read

Business

Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST

Therapeutic Solutions International, Inc., announced the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies.

September 7, 2021

·

2 min read

Eutilex To Present At The Biotech Showcase 2017 Conference

January 6, 2017

·

2 min read

Business

Eutilex Names Agustin de la Calle Chief Business Officer

November 8, 2016

·

3 min read

Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs

December 8, 2016

·

4 min read

Deals

Week in Review: China’s Creat to Restructure $1.5B Biotest Takeover

Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.

November 13, 2017

·

1 min read